Conference abstract · 26 Oct 2015
Conference abstractPublished 15 May 2017
CMC considerations for biosimilar drug development
Karl Ruprecht UniversitÃ?¤t, Germany
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Developing a biosimilar from a CMC perspective is a scientific and risk based approach and not a list with checkboxes to be ticked off. Following the quality strategy, the biosimilarity cannot be tested in the clinical trials but must be demonstrated on the drug substance and product level. For this, there are typical road maps always starting with a quality target product profile of the originator molecules. This talk will focus on typical analytical modules on the road map also touching the comparison of degradation profiles and impurities of biosimilar and originator molecules in a side-by-side analytical situation. All that must be adapted to the companyâÂ?Â?s strategy for market, time for development, budget and partners. Typical examples will be presented combined with pitfalls that companies are facing during the development.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract
Developing biosimilars: Considerations, opportunities and challenges
Conference abstract · 16 Sep 2020
Biosimilar Drug Development and Approval Process
Review article · 1 Oct 2019
Biosimilar Drug Development and Approval Process
Conference abstract · 15 Apr 2019
Sample size in biosimilar drug product development
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Label-Free Biosensing: Revolutionizing Disease Detection and Drug Discovery
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ulrike Konrad”

